• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer

Crypto Reporter

Online magazine about cryptocurrencies, NFTs, DeFi, GameFi and other blockchain technologies

Visit Consensus in Hong Kong | February 1-3, 2027
Visit Consensus in Miami | May 4-6, 2027
Use promo code CRYPTOREPORTER15 for a 15% discount on tickets
  • News
    • News Feed
    • Crypto news in brief
    • Stats & trends
  • Press Releases
  • Events
    • Upcoming Events
      • CryptoCon, Sydney (November 28–29, 2026)
      • iCrypto Awards: People’s Choice, Dubai (December, 2026)
      • Digital Asset Forum, London (February 1-2, 2027)
      • Consensus, Hong Kong (February 1-3, 2027)
      • Digital Assets Week, Dubai (February 4, 2027)
      • Digital Assets Week, Hong Kong (March 3, 2027)
      • 6th FinTech Week & Expo, Paris (May 4-5, 2027)
      • Consensus, Miami (May 4-6, 2027)
    • Past Events

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

October 1, 2025 By GlobeNewswire

SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that are immediately exercisable upon issuance and will expire five years from the effective date of a registration statement registering for resale the shares of common stock underlying the warrants.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering were approximately $2.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The common stock (but not the unregistered warrants and the shares of common stock underlying the unregistered warrants) described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-276658) that was declared effective by the Securities and Exchange Commission (the “SEC”) on January 30, 2024. The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering was filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

The unregistered warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Silo Pharma

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements pertaining to the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Contact

800-705-0120
investors@silopharma.com


Filed Under: News Feed

Primary Sidebar

Press Releases

Sky Protocol Shows Resilience Through Record $2 Billion Day as Review Finds CoinDesk Report Misleading

November 21, 2026

Tether Makes Strategic Investment in SCRYPT to Expand Institutional Stablecoin Infrastructure

November 20, 2026

Altius Labs Takes Stake in edgeX to Build “Any Asset, Anytime” Trading Infrastructure

November 20, 2026

I20 Summit to Bring World’s Largest Global Allocators to Miami Alongside G20 Leadership Summit

November 19, 2026

Global Kiwi Labs Raises $4M Seed Round Led by Valor Capital to Build the Physical Infrastructure Layer for Institutional Digital Asset Markets

November 19, 2026

iCrypto Awards

Digital Asset Forum, London (February 1-2, 2027)

Consensus, Hong Kong (February 1-3, 2027)

6th Fintech Week & Expo, Paris (May 4-5, 2027)

Consensus, Miami (May 4-6, 2027)

Footer

Crypto Reporter is an online magazine about cryptocurrencies, NFTs, DeFi, GameFi and other blockchain technologies
About us
Contact us
Submit press-release

Search

2017-2026 Crypto Reporter